Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits.

While initially, it might be hard to fully wrap your head around the concept of genomics, it’s easy to understand that companies ...

John Greene, a director at CRISPR Therapeutics AG (NASDAQ:CRSP), made a significant acquisition of the company's stock, according ...

More than a year after Vertex Pharmaceuticals and CRISPR Therapeutics won FDA approval for the world’s first CRISPR edited therapy Casgevy® (“exa-cel” or exagamglogene autotemcel ...